Dr Kiran Kancherla

Dr Kiran Kancherla is a highly-skilled clinical oncologist in the Midlands region. He specialises in the early and advanced treatment of breast cancer and prostate cancer, and treatments such as chemotherapy, radiotherapy (including stereotactic, image-guided, and intensity-modulated radiotherapies), immunotherapy, and targeted therapy.

Dr Kancherla qualified from the University of Health Sciences in 1997 and completed his registrar training in Leeds, where he gained experience in various modalities of cancer treatment, including endocrine therapy and biological agents. He became a member of the Royal College of Physicians in 2004, and in 2009 was made a fellow of the Royal College of Radiologists. He was qualified as an oncologist in 2010 after training in Leeds.

Dr Kancherla prioritises personalised and multidisciplinary approaches to treatment. In addition to his practice, he has been an investigator in several national and international clinical trials, has several publications in peer-reviewed cancer journals, and has contributed to abstracts which have been presented at both national and international conferences. He is a member of the European Society for Medical Oncology and the European Society for Radiotherapy and Oncology.

With over 25 years of experience as a medical doctor, Dr Kancherla is an experienced and accomplished oncologist with a holistic approach to cancer treatment that empowers his patients to make informed decisions during treatment, providing bespoke care tailored to individual patient needs and preferences. His practice philosophy is to use personalised medicine and a multidisciplinary team approach -- recommending treatments according to each patient's circumstances, based on scientific evidence and making best use of the expertise of key professionals involved in the various aspects of overall patient care.

Dr Kancherla offers treatment for:

• Breast cancer: hormone-positive, HER2-positive, triple-negative, inflammatory, DCIS, and BRCA cancers
• Prostate cancer: early stage, locally advanced, and advanced cancer

Utilising techniques such as:

• Systemic therapy: hormonal therapy, biological therapy, chemotherapy, immunotherapy, targeted therapy, anti-HER2 therapy, and radioisotope therapy
• Radiotherapy: stereotactic ablative body radiotherapy (SABR), MR Linac, intensity modulated radiotherapy (IMRT), VAMT, rapid arc, and IGRT